Skip to main content

ERI3 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 279 bp deletion in exon1.

Be the first to review this product! Submit a review

Images

Sanger Sequencing - Human ERI3 knockout HeLa cell lysate (AB263190), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Knockout validation
Sanger Sequencing
Mutation description
Knockout achieved by using CRISPR/Cas9, 279 bp deletion in exon1.

Alternative names

What's included?

1 Kit
Components
Human ERI3 knockout HeLa cell lysate
1 x 100 µg
Human wild-type HeLa cell lysate
1 x 100 µg

Recommended products

ERI3 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 279 bp deletion in exon1.

Key facts

Cell type
HeLa
Mutation description
Knockout achieved by using CRISPR/Cas9, 279 bp deletion in exon1.
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
ERI3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Storage

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Notes


Knockout cell lysate achieved by CRISPR/Cas9.

Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The ERI3 protein also known as EC-RNA Interacting Protein 3 functions mechanistically in the processing of RNA. This protein has a molecular mass of approximately 72 kDa. ERI3 expression occurs across several tissues with notable presence in the liver and kidneys. Its role in RNA processing makes it integral to various cellular processes that require accurate RNA management.

Biological function summary

ERI3 decapsulates mRNA influencing mRNA stability and turnover. This function positions ERI3 as essential in mRNA decay mechanisms. ERI3 doesn't work in isolation; it forms part of a multi-protein complex involved in mRNA decay and RNA processing activities. Studies suggest that it interacts directly with other key proteins in these complexes contributing to its biological significance.

Pathways

ERI3 plays a role in RNA degradation and nonsense-mediated mRNA decay pathways. It contributes to these pathways by interacting with proteins such as DCP2 and XRN1 which are important for mRNA turnover. This involvement ensures that cells maintain their mRNA levels and quality affecting overall protein synthesis necessary for cellular function.

Associated diseases and disorders

ERI3 shows a connection to liver cancer where its dysregulation impacts RNA decay processes linked to tumorigenesis. Another disorder associated with ERI3 is hereditary hemochromatosis although the connection is still under exploration. Within liver cancer the protein's relationship with DCP2 may influence disease progression highlighting ERI3's potential as a therapeutic target or biomarker.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image

  • Sanger Sequencing - Human ERI3 knockout HeLa cell lysate (ab263190), expandable thumbnail

    Sanger Sequencing - Human ERI3 knockout HeLa cell lysate (ab263190)

    Homozygous: 279 bp deletion in exon1

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com